Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer

Affiliations

• ¹ Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
• ² Department of Urology, Brigham & Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
• ³ Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
• ⁴ Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
• ⁵ Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
• ⁶ Harvard Medical School, Boston, MA, USA; Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA.
• ⁷ Department of Urology, Brigham & Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
• ⁸ Harvard Medical School, Boston, MA, USA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
• ⁹ Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Radiation Oncology, Brigham & Women's Hospital, Boston, MA, USA. Electronic address: kent_mouw@dfci.harvard.edu.